(Q37025897)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18062722%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Rosiglitazone : a review of its use in type 2 diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18062722%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18062722%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1

Emma D Deeks

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18062722%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18062722%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18062722%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18062722%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18062722%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

2747-2779

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18062722%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003495-200767180-00008

29 December 2019

exact match

0 references

cites work

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767180-00008

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767180-00008

Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency

21 January 2018

1 reference

12 December 2020

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

12 December 2020

Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.

1 reference

12 December 2020

Standards of medical care in diabetes--2007.

1 reference

12 December 2020

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

1 reference

12 December 2020

Effect of various diuretic treatments on rosiglitazone-induced fluid retention.

1 reference

12 December 2020

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

1 reference

12 December 2020

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

1 reference

12 December 2020

Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation

1 reference

12 December 2020

Effect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients

1 reference

12 December 2020

Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study

1 reference

12 December 2020

A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes.

1 reference

12 December 2020

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

1 reference

12 December 2020

Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death

1 reference

12 December 2020

Incretins and other peptides in the treatment of diabetes

1 reference

12 December 2020

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

1 reference

12 December 2020

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis

1 reference

12 December 2020

Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain.

1 reference

12 December 2020

Rosiglitazone RECORD study: glucose control outcomes at 18 months

1 reference

12 December 2020

Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells - role of PPAR-gamma in vascular fibrosis.

1 reference

12 December 2020

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes

1 reference

12 December 2020

Pharmacokinetics of rosiglitazone in patients with end-stage renal disease

1 reference

12 December 2020

Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.

1 reference

12 December 2020

Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.

1 reference

12 December 2020

Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea

1 reference

12 December 2020

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

1 reference

12 December 2020

Weight gain may contribute to increased fracture risk in women treated with rosiglitazone.

1 reference

12 December 2020

Can thiazolidinediones delay disease progression in type 2 diabetes?

1 reference

12 December 2020

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients

1 reference

12 December 2020

Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.

1 reference

12 December 2020

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

1 reference

12 December 2020

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study

1 reference

12 December 2020

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

1 reference

12 December 2020

Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy.

1 reference

12 December 2020

Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes

1 reference

12 December 2020

Coronary heart disease outcomes in patients receiving antidiabetic agents

1 reference

12 December 2020

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications

1 reference

12 December 2020

Effects of Chronic Rosiglitazone Therapy on Gene Expression in Human Adipose Tissuein Vivoin Patients with Type 2 Diabetes

1 reference

12 December 2020

Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

1 reference

12 December 2020

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

1 reference

12 December 2020

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

12 December 2020

Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers

1 reference

12 December 2020

A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

1 reference

12 December 2020

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

1 reference

12 December 2020

Rosiglitazone reduces urinary albumin excretion in type II diabetes

1 reference

12 December 2020

Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol

1 reference

12 December 2020

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

12 December 2020

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

12 December 2020

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

1 reference

12 December 2020

Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes

1 reference

12 December 2020

Lipids and lipoproteins in patients with type 2 diabetes

1 reference

12 December 2020

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus

1 reference

12 December 2020

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect

1 reference

12 December 2020

The rosiglitazone story--lessons from an FDA Advisory Committee meeting

1 reference

12 December 2020

The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

1 reference

12 December 2020

Rosiglitazone and cardiotoxicity--weighing the evidence

1 reference

12 December 2020

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

1 reference

12 December 2020

Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.

1 reference

12 December 2020

Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany

1 reference

12 December 2020

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

1 reference

12 December 2020

Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone

1 reference

12 December 2020

Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans

1 reference

12 December 2020

Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

1 reference

12 December 2020

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

12 December 2020

Oral antidiabetic agents in type 2 diabetes

1 reference

12 December 2020

Diagnosis and classification of diabetes mellitus

1 reference

12 December 2020

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

1 reference

12 December 2020

Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance

1 reference

12 December 2020

Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.

1 reference

12 December 2020

A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes

1 reference

12 December 2020

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

1 reference

12 December 2020

Rosiglitazone and cardiovascular risk

1 reference

12 December 2020

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

1 reference

12 December 2020

Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus

1 reference

12 December 2020

In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control

1 reference

12 December 2020

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

1 reference

12 December 2020

Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany--results from the CODE-2 study

1 reference

12 December 2020

Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes

1 reference

12 December 2020

Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

1 reference

12 December 2020

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

1 reference

12 December 2020

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

12 December 2020

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

12 December 2020

A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK

1 reference

12 December 2020

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

12 December 2020

PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells

1 reference

12 December 2020

The rosiglitazone meta-analysis

1 reference

12 December 2020

Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes

1 reference

12 December 2020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

12 December 2020

A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.

1 reference

12 December 2020

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

12 December 2020

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

1 reference

12 December 2020

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes.

1 reference

12 December 2020

Costs of type 2 diabetes in Germany. Results of the CODE-2 study

1 reference

12 December 2020

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

1 reference

12 December 2020

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats

1 reference

12 December 2020

Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury

1 reference

12 December 2020

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

12 December 2020